402 related articles for article (PubMed ID: 10974184)
1. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.
Memon MA; Blankenship JC; Wood GC; Frey CM; Menapace FJ
Am J Med; 2000 Aug; 109(3):213-7. PubMed ID: 10974184
[TBL] [Abstract][Full Text] [Related]
2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
3. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Bhatt DL; Topol EJ
JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
[TBL] [Abstract][Full Text] [Related]
4. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
Ciccone A; Motto C; Abraha I; Cozzolino F; Santilli I
Cochrane Database Syst Rev; 2014 Mar; (3):CD005208. PubMed ID: 24609741
[TBL] [Abstract][Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Lincoff AM; Califf RM; Topol EJ
J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948
[TBL] [Abstract][Full Text] [Related]
6. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Sabatine MS; Jang IK
Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186
[TBL] [Abstract][Full Text] [Related]
7. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.
Karvouni E; Katritsis DG; Ioannidis JP
J Am Coll Cardiol; 2003 Jan; 41(1):26-32. PubMed ID: 12570940
[TBL] [Abstract][Full Text] [Related]
8. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
9. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Proimos G
J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
[TBL] [Abstract][Full Text] [Related]
10. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ
Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331
[TBL] [Abstract][Full Text] [Related]
11. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
[TBL] [Abstract][Full Text] [Related]
12. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
[TBL] [Abstract][Full Text] [Related]
14. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Juran NB
Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235
[TBL] [Abstract][Full Text] [Related]
15. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
16. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC
Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
[TBL] [Abstract][Full Text] [Related]
17. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
Moliterno DJ;
Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
[TBL] [Abstract][Full Text] [Related]
18. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
Kimmelstiel C; Phang R; Rehman A; Rand W; Miele R; Rhofiry J; MacIsaac DA; Gouveia W; Denier D; Becker RC
J Thromb Thrombolysis; 2001 May; 11(3):203-9. PubMed ID: 11577258
[TBL] [Abstract][Full Text] [Related]
19. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
Dunn A
Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
[No Abstract] [Full Text] [Related]
20. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
Labinaz M; Ho C; Banerjee S; Martin J; Chen S; Mensinkai S
Can J Cardiol; 2007 Oct; 23(12):963-70. PubMed ID: 17932572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]